G-002 AMLODIPINE/VALSARTAN 5/160 MG VERSUS VALSARTAN 160 MG IN PREDOMINANTLY CHINESE PATIENTS WITH STAGE 1 OR 2 ESSENTIAL HYPERTENSION NOT ADEQUATELY CONTROLLED ON VALSARTAN 160 MG MONOTHERAPY

amie grosso,ying zhang,ruonan wang,dingliang zhu,kan yang,ningling sun,pingjin gao

DOI: https://doi.org/10.1097/01.hjh.0000408025.93495.df

IF: 4.9

2011-01-01

Journal of Hypertension

Abstract:Background Hypertension is a leading preventable risk factor for premature mortality among Chinese adults. We evaluated the efficacy and safety of amlodipine/valsartan 5/160 mg single-pill combination (SPC) for the treatment of hypertension in predominantly Chinese patients not adequately controlled on valsartan 160 mg monotherapy. Methods In this multinational study, 654 adults (82% Chinese) with stage 1 or 2 hypertension not adequately controlled with 4 weeks of valsartan monotherapy were randomized to receive double-blind valsartan 160 mg or amlodipine/valsartan 5/160 mg SPC once daily for 8 weeks. The primary efficacy variable was the change from baseline to endpoint in trough mean sitting diastolic blood pressure (MSDBP). Results Overall, the mean age of participants was 53.0 years and mean baseline blood pressure (BP) was 146.6/96.4 mmHg. Amlodipine/valsartan SPC reduced MSDBP to a greater extent than valsartan monotherapy: least-squared mean (LSM) changes (standard error [SE]) from baseline to endpoint were −10.3 (0.39) mmHg vs−6.6 (0.40) mmHg (p < 0.0001). The LSM changes (SE) from baseline to endpoint in mean sitting systolic blood pressure (MSSBP) were also greater with combination therapy than valsartan monotherapy: −14.9 (0.61) mmHg vs−7.0 (0.61) mmHg (p < 0.0001). A greater proportion of patients achieved MSSBP/MSDBP<140/90 mmHg with amlodipine/valsartan SPC vs valsartan monotherapy (61.3% vs 39.3%; p < 0.0001). Both treatments were well tolerated, with few adverse events reported (8.8% combination therapy, 11.7% monotherapy). Conclusion Amlodipine/valsartan 5/160 mg SPC was safe and effective therapy for lowering BP in predominantly Chinese adults with stage 1 or 2 hypertension not adequately controlled with valsartan 160 mg monotherapy.